Valeant Pharmaceuticals, parent company of Bausch & Lomb and other...

Valeant Pharmaceuticals, parent company of Bausch & Lomb and other operations, has reported an overall sales increase of 9 percent to $2.37 billion for the first quarter ended March 31, as compared to the restated turnover for the year-ago period, but the increase was mainly due to new acquisitions. In ...

To continue reading this article register now.

Already an Eyewear Intelligence subscriber? Sign in here.

barrier_image_OIC

Become a member today for full access from just €7,29 a week!

Buying a membership today will give you:

  • Unlimited access to ewintelligence.com - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation

Or sign-up for a trial month for just 9,90€. To continue reading this article register now.